Stockholm, Sweden — 21 January 2026 — Sigrid Therapeutics (Sigrid) is a Swedish, science-driven consumer health company with a primary focus on metabolic health. Following the successful launch of its first two clinically proven products — Carb Fence, designed to reduce appetite and cravings while supporting fat loss, lean muscle preservation, and post-meal blood sugar control, and Glucose Stabiliser, a dietary supplement designed to help regulate blood sugar after meals — Sigrid today announced that it has entered into an exclusive global licensing and research collaboration with a leading multinational consumer health company to expand the SiPore® technology platform into consumer oral health through a partner-led approach.

Stockholm, Sweden — January 7, 2026 — Sigrid, a Swedish innovation-driven consumer health company advancing metabolic health through non-systemic science, today announced a USD 5 million fundraise, bringing total capital raised to approximately USD 27 million. Participation from both existing and new international investors reflects strong confidence in Sigrid’s clinically validated platform and its accelerating commercial momentum in the United States.

Stockholm, Sweden — November 3rd — SIGRID, the Swedish innovative consumer care company behind the groundbreaking Glucose Stabiliser powered by patented SiPore® technology, today announced its expansion into the U.S. physician channel following a successful pilot program with selected integrative and functional medicine clinics.

Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore® technology, following the success of the SHINE study, the largest of its kind in prediabetes. The study demonstrated that Carb Fence™, a medical-grade, fast-acting liquid formula powered by SiPore®, effectively reduces long-term blood sugar levels HbA1c (A1C), improves glucose metabolism, and reduces body weight - while preserving muscle mass.

Follows successful e-commerce launch for innovative blood sugar management solution

Over 91% of U.S. and Swedish customers surveyed report that the 100% natural GLP-1 companion product provides more stable glucose levels, reduces bloating, and curbs the urge to snack

Sigrid Therapeutics announces that it has been granted a US patent for its SiPore® platform technology.

Sigrid Therapeutics announces the completion of the final patient visit in its SHINE clinical trial—the largest of its kind—surpassing the planned enrollment of 288 with a total of 318 participants.

Sigrid Therapeutics announces strategic partnership with GetHealthy.store for healthcare and nutritional products.

Sigrid Therapeutics announces the completion of enrollment for the SHINE clinical trial.

SiPore® SMART silica particles provide formidable first line defense against caries and plaque formation

SHINE is the largest ongoing clinical study of its kind, marking a milestone in research on prediabetes and weight control. It involves individuals who are living with excess weight or obesity and have prediabetes or type 2 diabetes.